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Summary Cell death by apoptosis is a major determinant of growth of normal tissues and tumours. The
present study aimed to elucidate signal factors involved in its regulation. Epithelial cells in control liver, during
regression of cyproterone acetate induced liver hyperplasia, in liver (pre)neoplasia and in uterus undergoing
apoptosis in vivo show immunostaining for transforming growth factor P1 (TGF-P1) as detected by anti-
pre(266-278) TGF-P1 antibodies. Positive immunostaining is also seen in a few intact cells of hyperplastic,
regressing liver apparently preparing for apoptosis, but is virtually not found in hepatocytes of normal or
growing liver nor in cells undergoing death by necrosis. Recombinant latency associated protein (rLAP, dimer
of the pro-region non-covalently associated with the mature region) complex and mature TGF-P1 induce
apoptosis in isolated hepatocytes cultured in vitro. These findings suggest an involvement of TGF-13I in the
induction of apoptosis in certain epithelia in vivo.
The pathogenesis of tumours in the liver and other organs
has been found to include disturbance of mechanisms con-
trolling cell death by apoptosis (Bursch et al., 1984; Colum-
bano et al., 1984; Garcea et al., 1984; Wyllie, 1985; Schulte-
Hermann et al., 1990; Henderson et al., 1991). Our previous
studies on the regulation of liver growth revealed that apop-
tosis serves to eliminate hepatocytes during involution of
hormonally induced liver hyperplasia and during carcino-
genesis in preneoplastic tissues (Bursch et al., 1984; Schulte-
Hermann et al., 1990). Tumour promoters inhibit apoptosis,
thereby accelerating growth of preneoplastic lesions and
occurrence of frank neoplasia in the liver (Bursch et al., 1984;
Schulte-Hermann et al., 1990). Furthermore, in hormone-
dependent tumours massive apoptosis can be induced by
hormone withdrawal or by hormone antagonists, resulting in
rapid tumour regression (Kyprianou et al., 1990; Szende et
al., 1990; Bursch et al., 1991). Therefore elucidation of signal
factors that can initiate apoptosis in hyperplastic and neo-
plastic tissues would be of great importance. Up to now
progess in understanding the regulation of apoptosis was
mainly restricted to hematological cells (Wyllie et al., 1980;
Duke & Cohen, 1986; Trauth et al., 1989; Savill et al., 1990;
Williams et al., 1990; Koury & Bondurant, 1990; Nunez et
al., 1990).
In epithelial tissues TGF-,11 was found to be a negative
regulator of growth. It inhibits DN-A synthesis in liver (Carr
et al., 1986; Russell et al., 1988), mammary gland (Coletta et
al., 1991), uterine endometrium (Rotello et al., 1991) etc. In
whole organ homogenates from prostate regressing after cast-
ration and from regressing tumours enhanced expression of
TGF-,1I was found suggesting its involvement in apoptosis
(Kyprianou et al., 1990; Kyprianou & Isaacs, 1989). In
primary cultures of uterine endometrial cells and of
hepatocytes TGF-,1I induced cell death (Rotello et al., 1991;
Oberhammer et al., 1991). In the present study we asked
whether TGF-P1 can be detected in individual dying cells of
involuting tissues in vivo using immunohistochemical techni-
ques with antibodies raised against two synthetic peptides of
the molecule. The first corresponds to the amino terminals 30
amino acids of mature TGF-P1 (LC(1-30)), the second to
amino acids 266-278 of the TGF-P1 precursor (Thompson et
al., 1989; Flanders et al., 1989). Anti LC(1 -30) stains intra-
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cellular mature TGF-p1, anti-pre(266-278) stains TGF-P1 in
its latent or newly synthesised form, but also cleaved parts of
the precursor molecule containing amino acids 266-278.
The results obtained indicate that (1) individual cells
undergoing apoptosis in vivo specifically respond with
antibodies against (pre-)TGF-PI and, albeit less pronounced,
against mature TGF-p1. (2) Necrotic liver cells did not show
any response to these antibodies. This finding may provide a
histological marker to discriminate between apoptotic and
necrotic cell death. (3) With anti-pre(266-278) apparently
intact hepatocytes preparing for apoptosis, but not yet in its
histologically detectable stages could be visualised. So far, no
other histological marker of apoptosis has been proven to
detect this early stage.
Furthermore, in cultured primary hepatocytes, TGF-P1 is
shown to be an inducer of apoptosis. In conclusion, the
present study strongly suggests the involvement ofTGF-P1 in
the control of apoptosis.
Materials and methods
Animals and treatment (in vivo studies)
Animals were treated according to published protocols
(Bursch et al., 1984, 1989). Briefly, cyproterone acetate (CPA,
Schering AG, Berlin, FRG) was dissolved in corn oil
(Mazola) and administered by gavage once per day to female
Wistar rats. The CPA-doses were 100 mg kg-' day-' for 3
days, followed by 130 mg kg-' day-' for 4 days (day 1-7).
Carbon tetrachloride was dissolved in corn oil (1:4, v/v) and
administered as a single dose (2ml kg-') by gavage to male
Wistar rats.
Histologicalprocedures
Liver and uterus specimens were fixed in Carnoy's fixative
and embedded in paraplast. Serial sections 5gcm thick were
exposed to anti-LC(1-30) and to anti-pre(266-278), kindly
provided by Dr M. Sporn, NCI, Bethesda, MD, USA. The
reaction was accomplished by the unlabelled antibody
peroxidase-antiperoxidase technique (Sternberger et al.,
1970). The sections were counterstained with Meyer's
hemalum.
The specificity of the TGF-,B1 antibodies used in our
studies was shown previously in control experiments per-
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formed by K. Flanders et al. (1989). Briefly, in various cell
types a positive immunostaining with anti pre(266-278) was
found to be colocalised with antibodies raised against the
amino acids 46-56 of precursor TGF-P1 as well as two
antibodies directed against the mature TGF-11 (antiLCI-30
and anti(50-75)). Further controls included preincubation of
antibody solution with TGF-1I sepharose which was
reported to result in reduced staining (Flanders et al., 1989).
For quantitative histological counts of apoptoses,
4000-6000 hepatocytes were scored per liver; the number of
apoptotic bodies was expressed as a percentage of normal
hepatocytes.
Cell culture studies
Hepatocytes were treated with 10 ng ml-' mature TGF-P1I
and 40 ng ml-' recombinant latency associated protein
(rLAP) complex (the dimer of the pro-region non-covalently
associated with the mature region; provided by Bristol-
Meyers-Squibb, Seattle, Wash., USA) for 48 h, other details
as previously published (Oberhammer et al., 1991).
Hepatocytes were fixed in 4% para-formaldehyde. Chromatin
was stained with Hoechst fluorochrom H33258, cytoplasmic
condensation and occurrence ofapoptotic bodies was demon-
strated by hematoxylin-eosin.
Results
First we studied apoptosis in rat liver. Hyperplasia was
induced by repeated administration of the hepatomitogen
a
cyproterone acetate (CPA) as described (Bursch et al., 1984);
upon cessation of CPA treatment extensive apoptoses led to
regression of hyperplasia within a few days (Bursch et al.,
1984).
Apoptosis is known to occur in a morphologically defined
sequence of events (Kerr et al., 1972, Wyllie et al., 1980). The
first of these is characterised by condensation ofchromatin at
the nuclear membrane (Figure la). Later stages are indicated
by fragmentation of cells and occurrence of extra and (after
phagocytosis) intercellular apoptotic bodies (AB; Figure
lb,c).
With anti LC(1-30) faint staining for mature TGF-P11 was
found in the liver, being more intense in the pericentral
region as has been shown previously (Thompson et al., 1989).
Some apoptotic bodies showed a clear cut positive response
with anti-LC(1-30). Quantitative counts revealed that app-
rox. 10% of the apoptotic bodies were positive; the majority
showed at best a faint staining.
Anti-pre(266-278) detected TGF-P1 in endothelial cells,
resulting in pronounced staining of the lining of the sinusoids
and correlating with the site of TGF-P1 gene expression
(Nakatsukasa et al., 1990, Jirtle & Meyer, 1991) (Figure
lb,c). In addition, most apoptotic cells and residues stood
out clearly positive outside and inside the negative paren-
chymal cells (Figure lb,c; cf. with d, non-immune IgG con-
trol). Due to its short duration (1-2 min; Bursch et al., 1990)
relatively few apoptotic cells were in the stage of chromatin
condensation. Of 60 cells found among 142,000 hepatocytes
scored 85% were positive for pre(266-278) TGF-P1 (Figure
la). ABs persist for an average of 3 h; they had an incidence
of 1-2% in the present study (Figure 2). In total 1462 ABs
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Figure 1 Immunocytochemical demonstration of the pro TGF-P1 in rat liver. a, hepatocyte exhibiting condensation of chromatin
positive for anti-pre(266-278) (4); b, extra-, c, intra-hepatocellular apoptotic bodies with chromatin positive for anti-pre(266-278)
(t), not positive endothelial cells (tt); d, liver exposed to non-immune rabbit serum, note negative endothelial cells and apoptotic
body (4); e, intact hepatocytes, positive for anti-pre(266-278) (4); f, balloonised (4) hepatocyte negative for anti-pre(266-278) at
12 h after a single oral dose of 2 ml kg-' carbon tetrachloride; positive hepatocyte (t).APOPTOSIS: INDUCTION BY TGF-PI 533
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Figure 2 Incidence of intact, pro TGF-P1 positive hepatocytes and apoptotic bodies in rat liver. CPA treatment: see Material and
methods section. Controls: received pure solvent (10 ml kg-'). CPA treatment: rats sacrificed between day 1-7, i.e. 24 h after the
respective last treatment. CPA withdrawal: rats sacrificed 2-3 days after last treatment. CPA retreatment: Treatment: day 1-7 as
above; day 8: no treatment; day 9: rats were treated with a single oral dose of 130 mg kg-' CPA. CPA was dissolved in an aqueous
solution of 0,09% Myrj (Serva, Heidelberg). Rats were sacrificed at 4 and 7 h. Juvenile liver: Female rats were killed 20 days after
birth. ( = ) intact hepatocytes positive for pro TGF-pl,-not detected in juvenile liver; ( p ) positive AB; (El ) negative AB.
Means are given, vertical bars indicate 95% confidence limits. Number of animals are indicated at the symbols, data of two
experiments were combined.
were analysed, approx. 70% of them were positive for
pre(266-278) TGF-P1 (Figure 2).
In serial sections a positive response with both antibodies
(anti-LC(1-30) and anti-pre(266-278) could be detected un-
equivocally in a few individual apoptotic bodies.
Remarkably, a number of apparently intact, vital
hepatocytes were found which unequivocally stained positive
for pre(266-278) TGF-P1 (Figure le). Their incidence signifi-
cantly correlated with that of apoptotic bodies in different
growth states, being virtually absent in growing liver of 3
week old rats, low in older control animals, and highest in
the regression phase following CPA withdrawal (Figure 2).
These hepatocytes were 15% smaller than the negative ones
and frequently showed concave walls (Figure le), indicating
cell shrinkage which is known to begin during early apoptosis
(Kerr et al., 1972, Wyllie et al., 1980). We therefore postulate
that these hepatocytes are preparing for apoptosis, but have
not yet entered its histologically visible stages.
Preneoplastic foci in the liver are known to exhibit high
apoptotic activity (Bursch et al., 1984; Schulte-Hermann et
al., 1991). Many of the apoptotic bodies as well as intact
hepatocytes in these foci stained positive for pre(266-278)
TGF-P1, similar to phenotypically normal liver. Likewise,
apoptoses in liver tumours were also found to contain
pre)266-278) TGF-P1 (not shown). Apparently, the involve-
ment of TGF-P1 in the control of apoptosis is preserved
during hepatocarcinogenesis.
Further we asked whether TGF-,1I is also associated with
cell death occurring after toxic injury in the liver. Rats were
treated with a necrogenic dose of carbon tetrachloride. At
12 h after intoxication numerous lytic and vacuolised
hepatocytes (pericentral zone) undergoing necrosis and bal-
loonised heptocytes (intermediate zone) were negative for
both pre(266-278) and mature TGF-P1 (Figure 1f). How-
ever, some apoptotic bodies and a few apparently intact
hepatocytes exhibited a positive response with anti-
pre(266-278) (Figure 0f). Likewise, after N-nitro-
somorpholine (250 mg kg- ) necrotic (lytic) hepatocytes
showed no immunoreactivity with anti-LC(1-30) or anti-
pre(266-278), whereas some apoptotic bodies were found to
be positive for pre(266-278) TGF-p1.
The positive immunostaining for (pre-)TGF-P1 in apopto-
tic liver cells does not prove its role for induction of cell
death, and if so, which part of the molecule is the active
factor. To address these questions we treated isolated primary
hepatocytes with recombinant mature TGF-,B or latency
associated protein (rLAP)-complex; the latter consists of the
pro region of the precursor (30 to 278) and mature TGF-P1
(279-390) (Miyazano et al., 1988; Gentry et al., 1988). We
have already shown that mature TGF-P1 can induce cell
death in cultured hepatocytes (Oberhammer et al., 1991). We
now found that both factors are active and produce the
characteristic signs of apoptosis, namely condensation of
chromatin with aggregation at the nuclear membrane (Figure
3a), and fragmentation of nucleus and cell, giving rise to AB
(Figure 3b,c). Electron microscopy revealed intact hepatocel-
lular organelles within these cell fragments (Oberhammer et
al., 1992), a major characteristic of apoptosis (Kerr et al.,
1972; Wyllie et al., 1980). In control cultures apoptotic cells
and AB were found very rarely. Mature TGF-P1 at the
concentration investigated increased the incidence of nuclei
with condensed chromatin to 2,2% (Figure 3d). The equi-
molar dose of LAP-complex also induced an increase, yet
about five times lower (0,37%; Figure 3d).
Physiological organ involution through apoptosis occurs in
the uterus post partum (Afting & Elce, 1978). In a single
experiment, in rat uteri 2 days post partum about 70 apop-
totic bodies among 14,000 cells scored were found, 67% of
them stained positive for pre(266-278) TGF-pl; no or only a
weakly positive reaction was observed with anti LC(I-30).
Thus, positive immunostaining or apoptotic bodies with
antibodies directed against TGF-P1 appears not to be
restricted to apoptoses during regression of chemically
induced liver hyperplasia.
Discussion
The present study aimed to test whether TGF-P1 is involved
in the control of apoptosis. In a first series of experiments,
antibodies raised against the mature and pre-form ofTGF-Pl
were used to ask whether TGF-P1 can be detected in individ-534 W. BURSCH et al.
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Figure 3 Apoptoses in primary hepatocyte culture after treatment with recombinant mature TGF-P1 and rLAP-complex. a,
normal hepatocyte nucleus (tt), hepatocyte exhibiting chromatin condensation typical of apoptosis (4), Hoechst 33258; b,c,
apoptotic bodies probably resulting from fragmentation of hepatocytes (4), H&E. d, Incidence of hepatocytes with condensation of
chromatin, counted after staining with Hoechst fluorochrom 33258. 3000-4000 hepatocytes were scored per treatment. Co: control;
( IEI¶) rLAP-complex, 40 ng ml -'; ( ) mature TGF-P1, 10 ngml -'. Means (± SD) of one representative experiment are shown.
ual dying cells in vivo. After exposing liver sections to the
antibody against the mature form of TGF-PI in 10% of
apoptotic bodies a positive response could be unequivocally
detected. With antipre(266-278) a pronounced staining of
apoptotic cells was found. Quantitative histological analysis
revealed that almost all apoptotic hepatocytes exhibiting
chromatin condensation (early histological stage of apop-
tosis) as well as 70% of apoptotic bodies (ABs) contain the
precursor form of TGF-p1. The negative response in 30% of
ABs may be due to advanced intracellular degradation in
later stages of the apoptotic process (Wyllie et al., 1980;
Bursch et al., 1990). Thus most if not all apoptotic hepa-
tocytes seem to contain the epitopes of anti-pre(266-278).
The failure to detect mature TGF-P1 in the majority of
apoptotic cells can probably be explained by its rapid deg-
radation. The biological half-life of the pre-form is about 2 h,
that of mature TGF-P1 is only 2 min. (Coffey et al., 1987;
Wakefield et al., 1990). Thus, once mature TGF-P1I is
formed, its rapid degradation should result in low levels in
apoptotic cells that may be insufficient for its unequivocal
immunocytochemical detection with the antibodies used.
Furthermore, we cannot rule out that anti-pre(266-278)
cross-reacts with other molecules involved in apoptosis.
However, we observed a colocalisation, albeit in only some
apoptotic bodies, of responses with anti-pre(266-278) and
anti-LC(1-30). A further line of evidence for the involve-
ment of TGF-P1 in apoptosis is provided by the cell culture
studies which show that both forms of TGF-P1 can induce
apoptosis of hepatocytes. These observations support our
hypothesis that our immunocytochemical findings indicate
the presence of forms of TGF-P1 in apoptotic hepatocytes.
In the present study also histologically intact hepatocytes
a b
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apparently preparing for apoptosis could be visualised with
the anti-pre(266-278) antibody. The duration of this
preparative, pre(266-278) TGF-,B1 positive stage can be
estimated by assuming that all positive hepatocytes are on
the pathway to apoptosis and hence their incidence is pro-
portional to the duration of this stage. Since this incidence
was similar to that of AB which persist in a visible form for
about 3 h (Bursch et al., 1990) the presence of TGF-11 in
hepatocytes prone to apoptosis likewise may last approx-
imately 3 h before chromatin condensation starts. Up to now
this preparative stage has not been detectable. The use of
(pre-)TGF-P1 antibodies as potential marker for pre-
apoptotic cells may render studies on early events in apop-
tosis possible.
Necrotic cells occurring in the liver after carbon tetra-
chloride or after N-nitrosomorpholine were found to be
negative for anti-pre(266-278) TGF-,13. However, in some
apoptotic bodies and apparently intact hepatocytes pre-TGF-
P1 was detected. Thus the corresponding epitopes may
specifically occur in apoptotic cells. This observation may be
of considerable interest in view of existing difficulties to
discriminate between apoptosis and necrosis. Furthermore,
our observations support previous reports that both necrosis
and apoptosis may take place after toxic liver injury (Wyllie,
1987).
In an experiment with regressing rat uterus post partum we
also observed a positive immunostaining of apoptotic bodies
with anti-pre(266-278). These findings in vivo are consistent
with recent observations in vitro on induction of apoptosis by
TGF-,13 in primary endometrial cells (Rotello et al., 1991).
They show that the appearance of pre(266-278) TGF-P1 in
apoptotic cells is not specific for hepatocytes, but may occur
in other epithelia as well.
In addition to the immunocytochemical analysis, studies
with primary hepatocyte cultures provided support for an
involvement of TGF-P1 in apoptosis. It was found that (1)
TGF-P1 can actively induce apoptosis; (2) TGF-B1 can
induce apoptosis as an extrinsic factor; (3) the greater
potency of mature TGF-P1 which was confirmed in four
independent experiments suggests that this may be the active
form. At present, we do not know the site of TGF-P1
synthesis and whether the increase of TGF-PI protein is
regulated at the transcriptional or post-transcriptional level.
In previous studies non-parenchymal cells of the liver but not
hepatocytes were found to express TGF-P1 (Carr et al., 1989;
Nagy et al., 1989). The apparent occurrence of (pre-)TGF-PI
selectively in hepatocytes involved in apoptosis could be
explained by uptake of TGF-PI through the mannose 6-
phosphate receptor (Jirtle et al., 1991) or by specific syn-
thesis. Studies on this question are in progress and will be
published elsewhere. In any event, the present in vivo and in
vitro data strongly suggest an involvement of TGF-,1I in the
initiation of apoptosis in hyperplastic and (pre)neoplastic
liver and possibly other epithelial tissues.
We would like to thank Drs A. Roberts, M. Sporn and K. Flanders
for providing the TGF-PI antibodies anti-LC(1-30) and anti-
pre(266-278).
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